Summary & Overview
HCPCS G2069: Monthly Buprenorphine Medication-Assisted Treatment Bundle
HCPCS Level II code G2069 designates a bundled, monthly medication-assisted treatment (MAT) service for injectable buprenorphine delivered by Medicare-enrolled opioid treatment programs. The code encompasses medication dispensing and/or administration plus integrated behavioral services—substance use counseling, individual and group therapy—and toxicology testing when performed. Nationally, this code is important as it aligns payment and documentation for comprehensive monthly MAT care, supporting continuity of treatment for opioid use disorder and enabling clearer billing for multi-component services. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise understanding of what services G2069 represents, the typical care settings where it applies, and the clinical context of bundled monthly MAT for injectable buprenorphine. The publication outlines payer coverage patterns, common billing modifiers and practical billing considerations, and policy or coding updates affecting MAT bundles. Where input data is incomplete, the report flags those fields as unavailable and focuses on the operational and clinical implications of using HCPCS Level II code G2069 for bundled monthly buprenorphine treatment.
Billing Code Overview
HCPCS Level II code G2069 describes a bundled, monthly medication-assisted treatment (MAT) service using injectable buprenorphine. The code represents a comprehensive package that includes dispensing and/or administration of the medication along with substance use counseling, individual and group therapy, and toxicology testing if performed when these services are provided by a Medicare-enrolled opioid treatment program.
Service type: Medication-assisted treatment bundle, monthly
Typical site of service: Opioid treatment program (OTP) enrolled with Medicare; outpatient behavioral health/substance use treatment settings where OTPs operate
Data not available in the input for associated taxonomies, specific ICD-10 diagnoses, related codes, and detailed service-line billing practices.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 32-year-old adult with moderate-to-severe opioid use disorder enrolled in a Medicare-enrolled opioid treatment program. The patient presents for a scheduled monthly visit for long-acting injectable buprenorphine. The visit includes medication administration, dispensing of the injectable buprenorphine product, a brief individual counseling session, enrollment in or continuation of weekly group therapy, and collection of a urine toxicology specimen when indicated. Nursing staff verify identity, vitals, medication allergies, and recent substance use; a licensed clinician documents substance use counseling and clinical decision-making; a behavioral health counselor provides individual and group therapy; and lab personnel perform point-of-care or send-out urine toxicology testing. The bundled service represented by G2069 is billed by the opioid treatment program for the combined monthly package of medication administration/dispensing, counseling (individual and group), and toxicology testing when performed. Typical site of service is an outpatient opioid treatment program or outpatient behavioral health clinic certified to provide medication assisted treatment. Common encounter workflow: patient check-in → nursing intake and urine collection (if indicated) → medication dispensing/administration → brief medical assessment and documentation → individual counseling session → group therapy scheduling/attendance → discharge planning and follow-up scheduling. The encounter frequently includes care coordination tasks such as prescription monitoring program checks and coordination with primary care or social services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|